Therefore, our findings indicate that PARPi treatment-associated p-STAT3 upregulation in ovarian cancer patient tumor-associated immune cells and CAFs may contribute to disease progression by promoting therapy resistance and immunosuppression. This evidence concerns the gene STAT3 and ovarian carcinoma.